Something old, something new-applications of accelerator mass spectrometry in translational medicine

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 53, Issue 5-6, 2010, Pages 300-304

  Garner, R Colin ^a,b  

^a Xceleron Ltd   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Absolute bioavailability; Accelerator mass spectrometry; ADME PK; Microdosing

Indexed keywords

BIOCHEMISTRY; DRUG PRODUCTS; PARTICLE ACCELERATORS; RADIOACTIVITY;

ABSOLUTE BIOAVAILABILITY; ACCELERATOR MASS SPECTROMETRY; ADME/PK; APPLICATION OF ACCELERATORS; ENABLING TECHNOLOGIES; MICRODOSING; NEW APPLICATIONS; RADIOLABEL; SPECIFIC RADIOACTIVITY; TRANSLATIONAL MEDICINE;

MASS SPECTROMETRY;

CARBON; CARBON 13; CARBON 14;

ACCELERATOR MASS SPECTROMETRY; ANALYTIC METHOD; CONFERENCE PAPER; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MACROMOLECULE; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR PHYSICS; RADIOACTIVITY;

EID: 77955162705     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1768     Document Type: Conference Paper

References (18)

1. J. A. DiMasi, R. W. Hansen and H. G. Grabowski, J Hlth Economics, 2003, 22, 151-185.
2. US Government Accountability Office, New Drug Development, GAO-07-49, GAO 2006.
3. www.fiercepharma.com/story/j-j-revenue-sees-first-decline-76-years/ 2009-01-21.
4. www.pharmafocus.com/cda/focusH/1,2109,22-0-0-FEB-2009-focus-feature- detail-0-492463,00.html
5. Challenge and Opportunity on the Critical Path to New Medical Products. US FDA Dept of Hlth Human Services 2004.
6. D. A. Katz, B. Murray, A. Bhathena and L. Sahelijo, Nature Rev Drug Discovery, 2008, 7, 293-305.
7. A. Roses, Nature Rev Drug Discovery, 2008, 7, 807-817.
8. Y. Sugiyama, Drug Disc Today, 2005, 10, 1577-1579.
9. www.pelletron.com/ssams14C.pdf
10. M. Stocker, M. Döbeli, M. Grajcar, M. Suter, H-A. Synal and L. Wacker, Nucl Inst Methods Phys Res Section B, 2005, 240, 483-489.
11. J. Barker J and R. C. Garner, Rapid Commun Mass Spectrom, 1999, 13, 285-293.
12. M. Gunnarson, K. Stenström, S. Leide-Svegborn, M. Faarinen, C-E. Magnusson, M. Åberg, G. Skog, R. Hellborg and S. Mattson, Appl Radn Isotopes, 2003, 58, 517-526.
13. G. Lappin, R. C. Garner, T. Meyers, J. Powell and P. Varley, J Pharm Biomed Anal, 2006, 41, 1299-1302.
14. A. Madan, Z. O'Brien, J. Wen, C. O'Brien, R. H. Farber, G. Beaton, P. Crowe, B. Oosterhuis, R. C. Garner, G. Lappin, H. P. Bozigian, Br J Clin Pharmacol, 2009, 67, 288-298.
15. G. Lappin, M. Rowland, R. C. Garner, Expert Opin Drug Metab Pharmacol, 2006, 2, 419-427.
16. R. C. Garner, Eur Pharmaceutical Contractor, 1999, 11, 22-28.
17. Guidance for industry, safety testing of drug metabolites, US FDA, February 2008.
18. N. Sarapa, P. H. Hsyu, G. Lappin, R. C. Garner, J Clin Pharmacol, 2005, 45, 1198-1205.